Morris MJ - Search Results

1

Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.

Rathkopf DE, Larson SM, Anand A, Morris MJ, Slovin SF, Shaffer DR, Heller G, Carver B, Rosen N, Scher HI. Rathkopf DE, et al. Among authors: morris mj. Cancer. 2015 Nov 1;121(21):3853-61. doi: 10.1002/cncr.29578. Epub 2015 Jul 15. Cancer. 2015. PMID: 26178426 Free PMC article. Clinical Trial.

2

Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.

Morris MJ, Tong WP, Cordon-Cardo C, Drobnjak M, Kelly WK, Slovin SF, Terry KL, Siedlecki K, Swanson P, Rafi M, DiPaola RS, Rosen N, Scher HI. Morris MJ, et al. Clin Cancer Res. 2002 Mar;8(3):679-83. Clin Cancer Res. 2002. PMID: 11895895 Clinical Trial.

3

HER-2 profiling and targeting in prostate carcinoma.

Morris MJ, Reuter VE, Kelly WK, Slovin SF, Kenneson K, Verbel D, Osman I, Scher HI. Morris MJ, et al. Cancer. 2002 Feb 15;94(4):980-6. Cancer. 2002. PMID: 11920466 Free article. Clinical Trial.

4

Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer.

Morris MJ, Akhurst T, Osman I, Nunez R, Macapinlac H, Siedlecki K, Verbel D, Schwartz L, Larson SM, Scher HI. Morris MJ, et al. Urology. 2002 Jun;59(6):913-8. doi: 10.1016/s0090-4295(02)01509-1. Urology. 2002. PMID: 12031380

5

Novel therapies for the treatment of prostate cancer: current clinical trials and development strategies.

Morris MJ, Scher HI. Morris MJ, et al. Surg Oncol. 2002 Jun;11(1-2):13-23. doi: 10.1016/s0960-7404(02)00006-3. Surg Oncol. 2002. PMID: 12031864 Review.

6

Fatal respiratory failure associated with treatment of prostate cancer using docetaxel and estramustine.

Morris MJ, Santamauro J, Shia J, Schwartz L, Vander Els N, Kelly K, Scher H. Morris MJ, et al. Urology. 2002 Dec;60(6):1111. doi: 10.1016/s0090-4295(02)01921-0. Urology. 2002. PMID: 12475686 Review.

7

Clinical approaches to osseous metastases in prostate cancer.

Morris MJ, Scher HI. Morris MJ, et al. Oncologist. 2003;8(2):161-73. doi: 10.1634/theoncologist.8-2-161. Oncologist. 2003. PMID: 12697941 Free article. Review.

8

Optimizing targeted therapy and developing novel outcome measures for patients with advanced prostate cancer at Memorial Sloan-Kettering Cancer Center.

Morris MJ, Scher HI. Morris MJ, et al. Crit Rev Oncol Hematol. 2003 Jun 27;46 Suppl:S21-31. doi: 10.1016/s1040-8428(03)00061-1. Crit Rev Oncol Hematol. 2003. PMID: 12850524 Review.

9

Targeting osseous metastases: rationale and development of radio-immunotherapy for prostate cancer.

Morris MJ, Pandit-Taskar N, Divgi C, Larson S, Scher HI. Morris MJ, et al. Curr Oncol Rep. 2004 May;6(3):222-9. doi: 10.1007/s11912-004-0053-y. Curr Oncol Rep. 2004. PMID: 15066234 Review.

10

High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma.

Morris MJ, Smaletz O, Solit D, Kelly WK, Slovin S, Flombaum C, Curley T, Delacruz A, Schwartz L, Fleisher M, Zhu A, Diani M, Fallon M, Scher HI. Morris MJ, et al. Cancer. 2004 May 1;100(9):1868-75. doi: 10.1002/cncr.20185. Cancer. 2004. PMID: 15112267 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

861 results

Search Page

Filters